Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Pharma
Astellas wins class-first gastric cancer nod for Vyloy
Astellas' Vyloy won an FDA approval to treat gastric or gastroesophageal junction adenocarcinoma patients whose tumors are CLDN18.2 positive.
Fraiser Kansteiner
Oct 18, 2024 3:39pm
AZ, Daiichi's Enhertu cleared by FDA in wide range of tumors
Apr 8, 2024 10:49am
PsiOxus is no more: Meet Akamis Bio
Jan 6, 2023 9:00am
TriSalus inks SPAC merger to fund infusion tech cancer trials
Nov 15, 2022 10:20am
Surge raises $26M to take anti-cancer hydrogel into the clinic
Oct 18, 2022 9:15am
Resilience teams with MD Anderson to accelerate cell therapies
Jun 3, 2022 10:34am
